학술

Exploring barriers and facilitators to Hepatitis C virus treatment access in Los Angeles County: A mixed-methods study

PLOS ONE
CC BY
이 매체는 공공·자유 라이선스로 본문을 직접 표시합니다.

Figures
Abstract
Diagnosed but untreated chronic Hepatitis C virus infection remains an important public health problem in Los Angeles County, particularly affecting underserved and minority groups. This mixed-methods study (October 2024-January 2025) aimed to identify and describe the barriers and facilitators to accessing Hepatitis C virus treatment among Los Angeles County residents. The study used de-identified programmatic data from 344 case-residents in a linkage-to-cure program and conducted thematic analysis of semi-structured interviews with ten participants (seven untreated, three treated) from the linkage-to-cure program. Overall, 54% of case-residents reported experiencing barriers. Among those reporting specific barriers (n = 91), personal barriers were most common (43%), followed by provider-related barriers (31%), insurance barriers (13%), and inadequate access to medical care (13%). Interviews provided further context. Themes identified included homelessness, incarceration, and drug addiction as key personal barriers. Provider-related barriers included language barriers, expressed frustration in navigating the healthcare system, long wait times to see a provider, and participants’ lack of HCV information. Insurance barriers were characterized by cost barriers and inadequate access to medical care due to a lack of transportation. Facilitators of treatment access included personal motivation to seek treatment, family and community-based support systems, trust in their medical provider, adequate insurance coverage, understanding the benefits of HCV treatment, and the desire to avoid stigmatization. Local efforts to eliminate Hepatitis C should consider equitable interventions that address individual and system-level barriers. Potential strategies include implementing language support services, leveraging patient navigation and care coordination services, utilizing mobile clinics for the unhoused, ensuring treatment continuity for people re-entering the community from incarceration, and removing insurance restrictions, such as prior authorization requirements.
Citation: Handa S, Sudeep N, Albers L, Pattarroyo M, Vasquez J, Montgomerie RE, et al. (2026) Exploring barriers and facilitators to Hepatitis C virus treatment access in Los Angeles County: A mixed-methods study. PLoS One 21(11): e0363327. https://doi.org/10.1371/journal.pone.0363327
Editor: Yury E. Khudyakov, Centers for Disease Control and Prevention, UNITED STATES OF AMERICA
Received: April 28, 2026; Accepted: November 7, 2026; Published: November 20, 2026
Copyright: © 2026 Handa et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The quantitative data and qualitative interview excerpts are available in the Figshare repository via DOI: 10.6084/m9.figshare.31476604.
Funding: Project activities were partially supported by USC and the Southern California Clinical and Translational Science Institute (https://sc-ctsi.org/nih-funding-acknowledgement), Grant #UL1TR001855 (received by JDK, DS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Background
Chronic Hepatitis C virus (HCV) infection is an asymptomatic infectious disease that affects the liver. Globally, Hepatitis C is a major cause of liver transplants [1]. Hepatitis C is primarily a result of blood-to-blood transmission, spread by needles shared during intravenous drug usage [2]. Without treatment, HCV-infected individuals can develop liver failure, liver cancer, cirrhosis, and die prematurely [1]. HCV infection can be cured with eight to 12 weeks of daily oral treatment with the use of direct-acting antiviral medication.
Hepatitis C virus in Los Angeles County
More than five million Americans, or around two percent of the American adult population, have anti-HCV antibodies, suggesting prior or current infection [3]. In Los Angeles (LA) County, California, 27,678 people were diagnosed with HCV between 2019 and 2023, but only 30% of people reported knowledge of HCV treatment [4]. Treatment completion rates remain low, with only 32% of people completing HCV treatment [5]. Notably, non-White minority groups, particularly Hispanic, Latino, or Black, had the lowest percentages of reported treatment completion [5].
Recent policy changes in Medi-Cal, such as the removal of prior authorization and prescriber restrictions for HCV treatment [6], were intended to improve access. However, significant obstacles remain, including structural issues in the healthcare system, provider-related practices, and patient-level factors such as stigma [7]. In particular, gaps remain in understanding the unique experiences of Spanish-speaking Latinx individuals, who represent a significant proportion of the untreated population.
Since healthcare experiences differ substantially between those who are untreated and treated, behavioral health frameworks are necessary to guide behavior change to receive HCV treatment. The Transtheoretical Model (TTM) helps researchers understand individual stages of change and therefore guided our decision to recruit and interview treated and untreated individuals. Additionally, findings were contextualized based on differences between treated participants, who likely reside in the action and maintenance phases, and untreated individuals, who are typically in the earlier phases of the TTM (e.g., precontemplation, contemplation, and planning). The Health Belief Model (HBM) has been used successfully in several studies of HCV infection [8–10]. Therefore, the interview guide for the present study was influenced by Health Belief Model (HBM) constructs such as perceived susceptibility, severity, threat, benefits, barriers, and self-efficacy [11]. The HBM provides a theory-driven way to examine the individual decision-making processes that may occur between HCV diagnosis and treatment initiation. We adapted the HBM to recognize that treatment initiation is influenced not only by individual beliefs but also by healthcare-system and structural factors identified as barriers to treatment adherence. Accordingly, HBM constructs were used to guide assessment of individual-level determinants of treatment-seeking, while additional domains examined insurance, healthcare access, provider-related barriers, and state and local policies. This approach allows us to distinguish potentially modifiable individual beliefs from structural barriers requiring health-system or policy interventions. Thus, the HBM provides both an explanatory framework for understanding the gap between HCV diagnosis and treatment and a theory-informed basis for identifying targets for future linkage-to-care interventions.
Methods
Study design and rationale
This study utilized a mixed-methods approach to evaluate the barriers and facilitators to accessing HCV treatment among LA County residents from October 2024 to January 2025. Data were derived from Project HCV Connect, a linkage-to-cure program based in LA County. We used a convergent parallel mixed-methods design, in which quantitative and qualitative data were collected during the same period, analyzed separately, and then merged during interpretation [12,13]. The quantitative component was prioritized. We combined the two approaches because linkage-to-cure data could show how often treated and untreated HCV individuals reported barriers and which types they reported, but not why those barriers occurred or how they shaped treatment decisions. Interviews with treated and untreated participants provided this context and allowed us to check whether participants’ accounts aligned with the program data.
Integration occurred at two points. First, at sampling. Interview participants were drawn from the same linkage-to-cure population as the quantitative data, and purposive sampling was based on treatment status, a variable recorded in the program data. Second, at interpretation. Quantitative barrier categories and qualitative themes were compared side by side in the Discussion to identify areas of convergence, expansion, and divergence.
Specifically, we attempted to answer the following research questions:
- (RQ1) Quantitative: What proportion of LA County residents face barriers to accessing treatment for HCV, and what are the specific barriers they experience?
- (RQ2) Qualitative: How do the experiences of treated and untreated LA County residents explain the barriers identified in the quantitative program data, and what additional factors do they identify as hindering or facilitating their HCV treatment journeys?
Participants and recruitment
In collaboration with the LA County Department of Public Health (DPH), the University of Southern California (USC) established Project HCV Connect, a linkage-to-cure program [14]. This program uses the LA County DPH’s HCV surveillance registry, which aggregates data from all laboratory-confirmed HCV-RNA-positive test results of non-incarcerated LA County residents aged 18 or older. Data are cross-referenced to create a person-level HCV registry by relating all HCV-RNA test results to unique persons (defined as case-residents). Program personnel contact case-residents via telephone, provide HCV education and assess whether residents are aware of their diagnosis, evaluate specific barriers preventing treatment, determine if they have taken steps toward treatment, and gauge if they are interested in linkage-to-cure services. Interested residents are linked to HCV treatment with their primary care provider, community health clinics, or a telehealth program, coordinated directly by the program personnel based on healthcare network and insurance coverage.
For the purposes of this study, we extracted and analyzed de-identified programmatic data to evaluate the barriers for case-residents during the analysis period. We invited a subset of those contacted to participate in a 30- to 60-minute semi-structured qualitative interview to explore the quantitative findings further. Participants met the inclusion criteria if (1) they had a confirmed HCV-RNA-positive result, (2) were LA County residents, and (3) were 18 years old or older. Interviews were conducted in English and Spanish.
Data collection
For the quantitative analysis, anonymous data were extracted from the linkage-to-cure program between October 2024 and January 2025. Data extracted included demographics (sex, age group, race/ethnicity), health insurance type, treatment status, willingness to receive treatment, and specific reported HCV barriers to treatment.
The TTM and HBM help explain treatment-seeking behaviors [11]. To understand why individuals choose or delay treatment and identify potentially modifiable factors for future interventions, interview guides were influenced by TTM and HBM and tailored to treated and untreated HCV study participants. Questions about treatment journey and medication adherence were asked of treated study participants, but not of untreated study participants. This allowed for the development of a targeted guide that assessed knowledge, attitudes, and beliefs among treated and untreated HCV study participants. Interview guides explored study participant-level treatment barriers, including stigma, insurance challenges, and health literacy, as well as facilitators such as strategies to improve treatment linkage.
Data analysis
The quantitative analysis is presented with descriptive statistics, utilizing frequencies and percentages. Data were analyzed using SAS Software Version 9.4. Inferential statistical analyses were not performed because the majority of sample sizes in specific sub-categories of reported barriers were n < 15, which would not support robust analyses.
For the qualitative part of the analysis, an inductive coding approach was employed to analyze interviews with untreated and treated study participants [15,16]. Thematic analysis was conducted through iterative coding of interview transcripts from study participant groups using Dedoose Version 9.2.22, a cloud-based qualitative analysis platform. To ensure analytical rigor, all transcripts were independently coded by members of the research team, including student volunteers and research staff. The research team then met regularly to compare codes and resolve coding discrepancies. Codes were developed collaboratively through repeated immersion in the data, with themes refined through comparative analysis across participant narratives. Although we did not conduct member-checking or participant transcript validation, our coders were content experts who have worked directly with HCV-positive individuals.
To contextualize and interpret qualitative findings, HBM constructs such as self-efficacy, perceived benefits, and perceived barriers provided a framework for interpreting exploratory findings [11]. TTM informed how findings were organized. Because treatment status reflects different stages of behavior change, findings were analyzed separately for untreated and treated participants and compared across the two groups [11]. TTM constructs were not coded or analyzed directly.
Results
From October 2024 to January 2025, LA County DPH case managers contacted 344 people with a reported HCV-positive test result. Among them, 168 (49%) were already treated for Hepatitis C, and 176 had not received any treatment. Table 1 indicates that 54% of the study participants faced barriers to Hepatitis C treatment. The most reported barriers to treatment were personal barriers, namely that it was not a personal health priority to start treatment, followed by issues with the medical provider, such as incomplete follow-up after initial visit. Lack of insurance and inadequate access to medical care were also barriers to HCV treatment.
We completed individual interviews with untreated study participants (n = 7) and treated study participants (n = 3). Of the untreated study participants, three were Spanish speakers, and four were English speakers. All three treated study participants were English speakers.
Barriers to accessing Hepatitis C treatment among untreated English and Spanish-speaking study participants
A total of twelve parent codes/themes were created for untreated study participant narratives (n = 7), and of those, barriers to linkage-to-cure include (1) the high cost of getting treated, (2) language barriers, (3) transportation to get to a medical provider, (4) lack of information, and (5) limited ability to navigate the healthcare system.
Cost barriers were most commonly cited, especially among the Spanish-speaking participants. Participants mentioned the high cost of insurance and personal or family financial instability that prevented them from initiating or continuing HCV treatment. Language barriers were also substantial concerns.
“Since I don’t speak 100% English, I was treated at the hospital in Los Angeles and one doctor was a liver doctor, the other one was a hepatitis doctor, the other one was a cirrhosis doctor, and I didn’t understand very well what they were telling me. And the medications were in English, and so I withdrew a little bit and I didn’t want to take care of myself anymore because I didn’t understand anything. Now I just changed… to another primary care doctor who explains it well in Spanish and in 20 minutes, he explained the hepatitis C.” (Untreated Spanish-speaking Study Participant #1)
Lack of information emerged as a significant theme across interviews, indicating that insufficient or unclear information about Hepatitis C and treatment options is a common experience. This theme reflects a patient-level gap in understanding Hepatitis C, its implications, and available treatments. The prevalence of this theme highlights a critical gap in community-level and patient education and the absence of health communication that may be contributing to treatment avoidance or delay. This knowledge gap emerged as a significant barrier to treatment engagement among the interviewed participants.
“I hadn’t heard so much about [HCV at the time of my diagnosis]… I don’t really know all that stuff about Hepatitis, what causes it or what is up with that.” (Untreated Spanish-Speaking Study Participant #2)
“Okay, all right, ‘cause I feel like a real dummy right now… I didn’t get this information [previously, but] even [the] little bit you’ve given me [during the interview], it makes sense.” (Untreated English-speaking Study Participant #5)
Frustration with navigating the healthcare system emerged as another prominent theme, particularly among Spanish-speaking participants. This theme reflects feelings of dissatisfaction or annoyance regarding healthcare experiences. It also captures broader discontent with the quality of care provided.
“I tried [to get treatment] before, but at least 3 or 4 times, and [they] all have been unsuccessful because of the blood draw process… I was an IV drug user, so I have collapsed veins… For test, [they need] sometimes two tests, not just one. I remember at one clinic, they were successful, albeit after a few tries, you know, of poking me with a needle. But the second [visit] was unsuccessful. And they needed that second blood test in order to prescribe medicine to treat it. And that second blood draw wasn’t successful.” (Untreated English-speaking Study Participant #3)
Preliminary observations among Spanish-speaking untreated participants suggest a potential trend toward frustration with their healthcare experiences, warranting further research regarding potential language-related or cultural barriers in provider-patient relationships. This frustration may further discourage engagement with the healthcare system for Hepatitis C treatment. Participants described experiences where they felt dismissed, not taken seriously, or treated impersonally by healthcare providers. These negative interactions appeared to create lasting impressions that discouraged future treatment-seeking behavior.
Facilitators of accessing Hepatitis C treatment among untreated English and Spanish-speaking study participants
Accessing hepatitis C treatment among untreated community members is facilitated by (1) high motivation to seek treatment and (2) the importance of support systems.
The motivation to seek treatment captures the internal and external drivers encouraging patients to pursue care for their HCV infection. The motivation theme was particularly prominent among Spanish-speaking study participants.
“Because, well yes, I have [HCV which] is going to make me sick in the future or I can pass [it] on to someone else. I think it is good to [seek treatment].” (Untreated Spanish-speaking Study Participant #2)
Having a support system was important among participants. This theme encompasses the role of personal, family, and other social networks in influencing treatment decisions. Desire for provider support/guidance was most frequent, familial support and clinician trust were also commonly discussed, and religious support was the least mentioned. The distribution of support system codes showed interesting patterns across language groups. Familial support was more evenly distributed across both language groups, indicating that family influence on treatment decisions is important regardless of language or cultural background. Spanish-speaking participants more frequently mentioned the desire for provider support/guidance, suggesting that Spanish-speaking untreated individuals may particularly value and need additional guidance from healthcare providers.
“I’ve been involved with the NA [Narcotics Anonymous] community. So that’s kind of like my support system, you know. We’re kind of open with each other, so there’s no judgment there, you know… they know my defects. We know each other’s, you know, defects and stuff. So that’s our support system. And I have some family, too, that understands what I’m going through.” (Untreated English-speaking Study Participant #3)
Barriers to accessing Hepatitis C treatment among treated English-speaking study participants
Among treated English-speaking study participants (n = 3), several treatment barriers emerged that prevented them from accessing timely HCV treatment. A total of six parent codes were created for treated study participant narratives, and of those, participants described four major barriers to HCV treatment that disrupted their treatment journey: (1) homelessness, (2) incarceration, (3) drug addiction, and (4) long wait times to see a provider.
For Treated English-speaking Study Participant #1, these challenges were deeply interconnected. He explained, “Yeah, I bet I was homeless. I was in and out of jail… These are kind of all of the, you know, the consequences of drug addiction, you know, which is how I got the Hep C [through] sharing needles.” His experience illustrates how overlapping life circumstances made it difficult to prioritize health or engage in care.
Treated English-speaking Study Participant #4 encountered structural barriers, such as delays in the referral process. “I find Hepatitis C, and my primary doctor referred me for [a] specialist. It took so long time to meet me,” she shared, expressing frustration that “to start my medication, I took 2 months to meet the doctor.” Her case underscores how even patients ready to begin treatment can face delays caused by fragmented care coordination and long waits for specialist access.
These barriers, whether rooted in social instability or healthcare system delays, significantly influenced access to timely and consistent Hepatitis C treatment.
Facilitators of accessing Hepatitis C treatment among treated English-speaking study participants
Despite their challenges, participants identified clear facilitators that helped them engage with care. These included (1) family support, (2) provider trust, (3) insurance coverage, (4) understanding the benefits of Hepatitis C treatment, and (5) the desire to avoid stigmatization.
Treated English-speaking Study Participant #1 emphasized how his wife helped keep him accountable. “She was always telling me, you know, ‘Did you take your meds?’… She wanted me to get healthy... because obviously she loves me, and she loves our family.” Her encouragement made adherence feel like a shared responsibility rooted in love and concern. The birth of a child also served as a powerful motivator. The same treated participant described how fatherhood shifted his perspective: “Once that happened, and then the birth of my son happened shortly after that. It just gave me this new lease on life, and was just like, hey man… you’re not getting younger. You need to get healthier. You need to be there. You need to be around for your kids.”
He also reflected on the impact of provider communication. “If they say this is a good idea, then I’m gonna do it,” he said, underscoring how confidence in his care team helped him move forward with treatment.
Insurance played a critical role. Treated English-speaking Study Participant #1 shared, “I’m just on Medi-Cal, you know, regular medical insurance, and they covered it fully... everything was from the specialist to my GP... It was very easy... one of the easier things I had to do.” For him, comprehensive Medi-Cal coverage eliminated financial stress and simplified care access.
After completing treatment, participants described the benefits of treatment, specifically the improvements to both their physical health and sense of self. Treated English-speaking Study Participant #4 said the medication allowed her to return to her normal routine. “[I’ve] improved. I am back for the normal life,” she said. “I’m active now, I can do everything.” She associated recovery with regaining control over daily life and being able to care for her family again. Treated English-speaking Study Participant #1 described a deep emotional shift. “It made me feel like a real adult... I’m being responsible for my kids. I’m being responsible for my wife. I’m doing all these things, you know, after living a life of risk taking behavior that led to me getting a hep C.” For him, treatment wasn’t just about eliminating the virus. It was about rebuilding a stable and purposeful life.
Participants also expressed that the stigma associated with Hepatitis C shaped their sense of urgency to pursue care. Treated English-speaking Study Participant #1 recalled avoiding physical contact, saying, “I can’t shake your hand right now... Well, I’m bleeding... what does that mean?” This discomfort reflected internalized judgment from others, even when the risk was low. The desire to eliminate ongoing stigmatization and embarrassment motivated them to seek treatment.
Discussion
This mixed-methods study allowed for an in-depth exploration of barriers and facilitators to Hepatitis C treatment access. A comparison of quantitative survey data and qualitative interview themes reveals critical areas of convergence and nuance regarding patient experience. This study highlights the complex interplay of linguistic, socioeconomic, and systemic factors that must be addressed to positively influence treatment engagement and outcomes.
Personal barriers exploration
Quantitative responses indicated that personal and provider-specific barriers were the most commonly reported barriers to care, and a lack of understanding of the impact of the infection or prioritizing treatment seem to be important reasons for not initiating treatment. Multiple reasons that explain deprioritizing or delaying treatment have already been reported in the literature. Personal circumstances, such as insurance status, housing security, incarceration, and substance use, significantly shape the landscape of Hepatitis C treatment engagement and continuation [5,7,17,18]. Local elimination programs attempt to reach these vulnerable populations [19] by implementing screening and treatment programs and resources in high HCV prevalence settings such as jails, among persons experiencing homelessness, and in syringe service programs. Broader community programs could supplement these efforts and increase general awareness about hepatitis and these resources.
Another potential reason that could delay treatment is understanding of diagnosis, as it was highlighted during interviews. Structured patient education is an integral part of medical care, and it is an effective strategy for improving HCV knowledge in vulnerable populations and may promote better engagement with care and treatment [20]. Language barriers and frustration navigating the healthcare system emerged as themes that also hinder access and result in negative provider interactions. Language proficiency can be a barrier to accessing Hepatitis C treatment among migrant populations. Spanish-speaking immigrants often report that a lack of translated materials and culturally sensitive services prevents them from understanding their risk or the benefits of newer treatments [21]. This challenge is highlighted in a narrative review by Escobedo et al. [21], which evaluated studies across U.S. inpatient hospitals and outpatient clinics. The authors found that limited English proficiency among Latinx populations drives medical mistrust, compromises patient comprehension of medical instructions, and significantly reduces overall care utilization. Although preliminary, our exploratory findings that Spanish-speaking participants frequently experienced frustration and a greater need for provider guidance are consistent with prior evidence showing that language support in viral hepatitis care can improve adherence, health outcomes, and highlight a potential avenue to address and potentially bridge the Hepatitis C treatment gap [22]. In a multi-country exploratory survey evaluating primary care and specialist settings across six European countries, Falla et al. [22] found that clinicians widely identified language barriers as a root cause for low hepatitis screening rates among linguistic minority populations. The study noted that a lack of formal interpreters and translated materials hinders diagnosed patients from successfully transitioning to specialist clinical care. Moving further, it is important to develop culturally appropriate patient resources and make them available in clinic and public settings.
Social facilitators to treatment
This study’s findings emphasize the importance of social facilitators as an opportunity for healthcare providers to leverage motivation and convert it into treatment-seeking behavior. A high proportion of untreated study participants were highly motivated to seek treatment and cure their infection. Outreach strategies should highlight the benefits of treatment to their health, i.e., the decreased likelihood of liver cancer, and the opportunity to protect loved ones from infection, which may convince people to get treatment. Amoako et al. [17] reported that family, especially having children, shifts the perspective on patient health and acts as a facilitator of Hepatitis C treatment. This facilitation is driven by a sense of familial duty, where pursuing treatment is viewed as a way to fulfill one’s responsibilities to loved ones and ensure the well-being of the entire household [23]. In addition, Evon et al. [24] identified additional facilitators of treatment, including better future quality of life and achieving an HCV-uninfected status. Furthermore, qualitative insights revealed that while stigma can act as a motivator for some seeking to eliminate a source of judgment [17], it remains a deterrent among immigrant populations [25]. These observations highlight the need to place personal benefits, altruistic motivations (such as protecting family and friends), and family support at the center of patient outreach, counseling, and navigation efforts. Further research should attempt to develop messaging and delivery and evaluate the impact on treatment initiation.
Care-associated costs and insurance as a burden
However, those social motivators can be undermined by the harsh realities of economic instability. Qualitative interviews emphasized cost as a barrier to care, while quantitative findings identified other barriers as more frequently reported. Although most program participants had some form of insurance, insurance-related obstacles can cause delays. Adequate health insurance coverage helped interviewed treated participants, but our previous research in Los Angeles County has shown that, even among those with insurance, there are low proportions of treated individuals ranging from 65.9% to 70.5%, with the highest rate among uninsured [18]. Research shows that Medicaid recipients face longer wait times for care than those with private coverage, suggesting that insurance type and status are critical determinants of timely Hepatitis C treatment [26]. While California removed prior authorization restrictions for the State Medicaid program (Medi-Cal) in 2024, this change does not apply to non-state or private insurance programs. The recent California Assembly Bill 1843, which will be enacted in 2027, will prohibit most health plans and insurers from requiring prior authorization for HCV medications [27]. We hope that this will increase access to treatment for many residents of California, although efforts would be necessary to increase awareness of this new bill.
Implications for clinical practice and policy
Our exploratory findings offer valuable preliminary insights for clinical practice and localized public health policy initiatives in LA County. Healthcare systems must prioritize patient navigation and care coordination services, comprehensive language support services, including professional medical interpretation, and culturally tailored patient education materials. Culturally competent healthcare staff is also important. Addressing negative healthcare experiences through improved provider communication and patient-centered care approaches could enhance treatment engagement and reduce healthcare system avoidance. Policy interventions focused on expanding insurance coverage, reducing treatment costs, and eliminating prior authorization requirements warrant consideration as potential strategies to improve access to Hepatitis C treatment. By understanding specific local barriers, we can more effectively inform and strengthen local Hepatitis C elimination efforts, such as the LA County Viral Hepatitis Action Plan [19].
Limitations
Due to the small number of participants who provided details on specific treatment barriers, our quantitative analysis was restricted to descriptive statistics. We were unable to conduct inferential modeling to evaluate disparities across race/ethnicity, language, or insurance status. The qualitative component of this study was framed as an exploratory analysis to gain preliminary insight into individual lived experiences. However, the small qualitative sample size may limit the generalizability of our findings to the broader population of LA County. Furthermore, because the qualitative sample is unevenly distributed between untreated and treated individuals, our findings may not reflect the full spectrum of barriers and facilitators affecting Hepatitis C treatment engagement. While the inclusion of Spanish-speaking participants represents a significant strength of this study – reflecting a critical demographic within LA County – this focus may not fully capture the experiences of other linguistic minorities in the region, necessitating future research into diverse immigrant and refugee communities to develop a more comprehensive understanding of the linguistic and cultural factors affecting HCV treatment.
References
- 1. Manns MP, Buti M, Gane E, Pawlotsky J-M, Razavi H, Terrault N, et al. Hepatitis C virus infection. Nat Rev Dis Primers. 2017;3:17006. pmid:28252637
- 2. Stroffolini T, Stroffolini G. Prevalence and modes of transmission of hepatitis C virus infection: A historical worldwide review. Viruses. 2024;16(7):1115. pmid:39066277
- 3. Saab S, Le L, Saggi S, Sundaram V, Tong MJ. Toward the elimination of hepatitis C in the United States. Hepatology. 2018;67(6):2449–59. pmid:29181853
- 4.
Los Angeles County Department of Public Health. Viral Hepatitis | ACDC. [cited 2026 Feb 24]. Available from: http://ph.lacounty.gov/acd/diseases/hepatitis/home.htm
- 5. Hernandez-Tamayo C, Stafylis C, Bhardwaj L, Shah RK, Becerra T, Bruce D, et al. Determinants of hepatitis C virus treatment completion among Los Angeles County residents. BMC Infect Dis. 2025;25(1):1364. pmid:41120963
- 6.
Hepatitis C: State of Medicaid Access Report Card - California. State of Hep C; 2025. [cited 2026 Feb 24]. Available from: https://stateofhepc.org/wp-content/uploads/2025/12/California-Nov-2025_Clean.pdf
- 7. Harris M, Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: A review mapping the role of social factors. Harm Reduct J. 2013;10:7. pmid:23651646
- 8. Owiti JA, Greenhalgh T, Sweeney L, Foster GR, Bhui KS. Illness perceptions and explanatory models of viral hepatitis B & C among immigrants and refugees: A narrative systematic review. BMC Public Health. 2015;15:151. pmid:25886390
- 9. Rashrash ME, Maneno MK, Wutoh AK, Ettienne EB, Daftary MN. An evaluation of hepatitis C knowledge and correlations with health belief model constructs among African American “baby boomers”. J Infect Public Health. 2016;9(4):436–42. pmid:26706773
- 10. Pundhir P, North CS, Fatunde O, Jain MK. Health beliefs and co-morbidities associated with appointment-keeping behavior among HCV and HIV/HCV patients. J Community Health. 2016;41(1):30–7. pmid:26179172
- 11.
Glanz K, Rimer BK, Viswanath K, editors. Health behavior and health education: Theory, research, and practice. 4th ed. San Francisco, CA: Jossey-Bass; 2008.
- 12. Fetters MD, Curry LA, Creswell JW. Achieving integration in mixed methods designs-principles and practices. Health Serv Res. 2013;48(6 Pt 2):2134–56.
- 13. Morgan DL. Failure to converge? The use of convergent designs in mixed methods research designs in mixed methods research. PDXScholar; 2025 [cited 2026 Oct 12]. Available from: https://pdxscholar.library.pdx.edu/cgi/viewcontent.cgi?article=1214&context=soc_fac
- 14. Stafylis C, Hernandez-Tamayo C, Bhardwaj L, et al. Project HCV Connect: Using a county surveillance registry to link hepatitis C virus-infected residents to cure - Los Angeles County, April 2023 to March 2024. J Public Health Manag Pract. 2025;31(4):610–3.
- 15. Fleming CJE. Qualitative methods for the quantitatively inclined. Center for Engaged Learning; 2023 [cited 2026 Feb 24]. Available from: https://www.centerforengagedlearning.org/qualitative-methods-for-the-quantitatively-inclined/
- 16. Maietta R, Mihas P, Swartout K, et al. Sort and sift, think and shift: Let the data be your guide, an applied approach to working with, learning from, and privileging qualitative data. Qual Rep. 2021;26(6):2045–60.
- 17. Amoako A, Ortiz-Paredes D, Engler K, Lebouché B, Klein MB. Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis C treatment among priority populations in high income countries: A knowledge synthesis. Int J Drug Policy. 2021;96:103247. pmid:33853727
- 18. Lopez H, Klausner JD, Stafylis C. Re: Racial and sociodemographic disparities in hepatitis C treatment at an urban academic medical center, 2018-2023. Open Forum Infect Dis. 2025;13(1).
- 19.
Los Angeles County Department of Public Health. Los Angeles County viral hepatitis action plan; 2022 [cited 2026 Feb 24]. Available from: http://ph.lacounty.gov/acd/diseases/hepatitis/docs/LACViralHepActionPlan.pdf
- 20. Surjadi M, Torruellas C, Ayala C, Yee HF Jr, Khalili M. Formal patient education improves patient knowledge of hepatitis C in vulnerable populations. Dig Dis Sci. 2011;56(1):213–9. pmid:20972850
- 21. Escobedo LE, Cervantes L, Havranek E. Barriers in healthcare for Latinx patients with limited English proficiency-A narrative review. J Gen Intern Med. 2023;38(5):1264–71. pmid:36720766
- 22. Falla AM, Veldhuijzen IK, Ahmad AA, Levi M, Richardus JH. Language support for linguistic minority chronic hepatitis B/C patients: An exploratory study of availability and clinicians’ perceptions of language barriers in six European countries. BMC Health Serv Res. 2017;17(1):150. pmid:28219385
- 23. Davila YR, Reifsnider E, Pecina I. Familismo: Influence on Hispanic health behaviors. Appl Nurs Res. 2011;24(4):e67-72. pmid:20974085
- 24. Evon DM, Golin CE, Bonner JE, Grodensky C, Velloza J. Adherence during antiviral treatment regimens for chronic hepatitis C: A qualitative study of patient-reported facilitators and barriers. J Clin Gastroenterol. 2015;49(5):e41-50. pmid:24828358
- 25. Mortazhejri S, Thomas IM, Patey AM, Alghamyan A, Cooper C, Mansour S, et al. Perceptions about hepatitis C and barriers and enablers to screening and treatment among Egyptian immigrants to Canada: A theory-informed qualitative study. Int J Equity Health. 2025;24(1):203. pmid:40646616
- 26. Thompson WW, Symum H, Sandul A, DHSc, Gupta N, Patel P, et al. Vital signs: Hepatitis C treatment among insured adults - United States, 2019-2020. MMWR Morb Mortal Wkly Rep. 2022;71(32):1011–7. pmid:35951484
- 27.
California Assembly Bill 1843, Elhawary. Communicable Diseases: Hepatitis C. Chapter 552, Statutes of 2026; 2026 [cited 2026 Oct 12]. https://legiscan.com/CA/text/AB1843/id/3457961

관련 뉴스